Olympus Announces Plan to Establish Digital Excellence Centers Following Acquisition of Cloud-AI Endoscopy Startup Odin Vision

Olympus, a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, announced the plan to establish a series of Digital Excellence Centers (DECs) following acquisition of London-based Odin Vision, a cloud-AI endoscopy company with a strong portfolio of commercially available computer-aided detection/diagnostic solutions and innovation pipeline of cloud-enabled applications.

The acquisition has strengthened Olympus’ recently announced strategy and initiatives in digital health and brings the promise of AI-powered real-time diagnosis and minimally invasive treatment of chronic diseases closer to reality, ultimately raising the standard of care across multiple medical specialties and improving patient outcomes.

Envisioning an intelligent endoscopy ecosystem for the benefit of patients and healthcare providers

Odin Vision is contributing to Olympus’ vision of the future of endoscopy. Combining the strength of its core endoscopy portfolio with innovative digital solutions, Olympus plans to collect and analyze procedural, clinical and medical device data in real time, and then, powered by a new, modern digital platform leveraging the latest AI algorithms and software, provide healthcare professionals with clinical and operational solutions designed to reduce administrative and cognitive burdens while also improving operational efficiency. These advancements will support healthcare institutions as they endeavor to raise their level of care.

“As a leader in endoscopy and innovator in the space, Olympus is passionate about delivering the next generation of intelligent integrated solutions and insights to healthcare providers,” said Shawn LaRocco, Global VP Customer Solutions, responsible for the digital health business at Olympus. “However, we cannot do it alone and are continuously looking to partner with other pioneers like Odin Vision who share this passion.”

Digital Excellence Centers to push the envelope of creative innovation

To enable this commercial strategy, Olympus plans to develop and establish DECs for the development of digital solutions around the world, beginning in London where the acquisition of Odin Vision has laid the groundwork. In addition to its portfolio, Odin Vision brings renowned AI and software expertise and development capabilities that synergize and further accelerate Olympus’ digital health strategy. DECs are to be located at current Olympus R&D sites in Hamburg, Boston and Tokyo, with the possibility of expanding to Silicon Valley and Tel Aviv at a later stage.

Peter Mountney, Ph.D., CEO of Odin Vision commented, “We are excited to set the stage for future innovation development by leading Olympus’ plans for the first DECs, all in the pursuit of empowering clinicians to deliver the best possible care and outcomes to patients using the latest digital and AI tools.”

“As Olympus looks to expand development capabilities in digital solutions, establishing DECs around the globe will allow us to access critical talent and to develop partnerships with start-ups and other companies who, like Odin Vision, are pushing the envelope of creative innovation,” said Karsten Klose, Global Head of Digital at Olympus.

Olympus and Odin Vision at HIMSS23

Olympus and Odin Vision will be at HIMSS23 European Healthcare Conference & Exhibition, from June 7 to 9, in Lisbon, Portugal.

– On stage: Olympus and Odin Vision will be on stage from 11:00-11:50 on Friday, June 8, at the center stage in the Centro de Congressos de Lisboa. They will discuss how digital solutions like Odin Vision’s are being integrated into patient care, leading to better outcomes.
– In the exhibition: Olympus will be present at the congress on June 8 and 9 can be found in Booth 826.

SourceOlympus

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.